Figure 1: Effect of pemafibrate and fenofibrate on hepatic steatosis. | Scientific Reports

Figure 1: Effect of pemafibrate and fenofibrate on hepatic steatosis.

From: Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis

Figure 1

(A) Liver sections from BD, CTRL, PEMA-L, PEMA-H, and FENO mice. Haematoxylin and eosin staining, (B) oil red O staining. Magnification, 100×. Scale bars: 200 μm. (C) Areas of oil red O staining in the liver of BD, CTRL, PEMA-L, PEMA-H, and FENO mice (n = 5). (D) Triglycerides content were measured in the livers of BD, CTRL, PEMA-L, PEMA-H, and FENO mice (n = 5). Results are the mean ± SE. Significance was determined using Student’s t-test (†p < 0.05 versus CTRL mice) or Dunnett’s test (*p < 0.05 versus CTRL mice).

Back to article page